Dr. Lee on the Role of Darolutamide in M0CRPC

Richard JaeBong Lee, MD, PhD
Published: Tuesday, Jun 25, 2019



Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the role of darolutamide in nonmetastatic castration-resistant prostate cancer (M0CRPC).

It is difficult to define darolutamide’s role in the prostate cancer paradigm, as apalutamide (Erleada) and enzalutamide (Xtandi) are 2 effective drugs that have already received FDA approval for use in this space. There is a lot of clinical experience with both of those drugs, says Lee. Whether or not darolutamide provides an improvement is difficult to know. All 3 drugs have demonstrated improvement metastasis-free survival, but there might be slight differences between them in terms of efficacy and safety profiles; these differences may help inform which agent to prescribe when they are all indicated in this setting. Other aspects that could be considered include the financial toxicity of these therapies; however, the cost of this category of drugs appears to be somewhat comparable with a similar impact for patients, adds Lee. As such, financial toxicity may not drive selection of the agent.
SELECTED
LANGUAGE


Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the role of darolutamide in nonmetastatic castration-resistant prostate cancer (M0CRPC).

It is difficult to define darolutamide’s role in the prostate cancer paradigm, as apalutamide (Erleada) and enzalutamide (Xtandi) are 2 effective drugs that have already received FDA approval for use in this space. There is a lot of clinical experience with both of those drugs, says Lee. Whether or not darolutamide provides an improvement is difficult to know. All 3 drugs have demonstrated improvement metastasis-free survival, but there might be slight differences between them in terms of efficacy and safety profiles; these differences may help inform which agent to prescribe when they are all indicated in this setting. Other aspects that could be considered include the financial toxicity of these therapies; however, the cost of this category of drugs appears to be somewhat comparable with a similar impact for patients, adds Lee. As such, financial toxicity may not drive selection of the agent.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x